These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 29291712)

  • 1. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
    Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
    Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
    Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
    Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY
    Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
    Annibali O; Hohaus S; Marchesi F; Cantonetti M; Di Rocco A; Tomarchio V; Di Napoli A; Pelliccia S; Battistini R; Anticoli Borza P; Abruzzese E; Cenfra N; Andriani A; Tesei C; Alma E; Palombi F; Pupo L; Petrucci L; Becilli M; Maiolo E; Bellesi S; Cuccaro A; D'Alò F; Cox MC
    Leuk Lymphoma; 2019 Dec; 60(14):3386-3394. PubMed ID: 31259651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.
    Zhou S; Xu L; Ma Y; Tang L; Zhang Y; Shi Y; Sun L; Chen Y; Liang B; Zhou Y; Yu K; Shen J
    Oncotarget; 2017 Mar; 8(12):19556-19565. PubMed ID: 28107187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.
    Beltrán BE; Paredes S; Cotrina E; Sotomayor EM; Castillo JJ
    Leuk Res; 2018 Apr; 67():82-85. PubMed ID: 29477024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
    Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
    PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
    Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.
    Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Shi Y
    Leuk Res; 2021 Nov; 110():106715. PubMed ID: 34598076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
    Go SI; Kim HG; Kang MH; Park S; Lee GW
    BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.